PharmaEssentia Corp.

Booth 743
Taipei, Taiwan
PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). Our flagship product, BESREMi, was approved by FDA in 2021 for all-comers polycythemia vera.